A newly published study in Engineering describes live-cell glycocalyx engineering strategies to advance adoptive cell therapies targeting B lymphoma. The work addresses persistent barriers in ACTs, including cost and limited antigen specificity, by engineering cell-surface features intended to improve targeting and functional performance. By focusing on glycocalyx modification in live cells, the researchers outline an engineering route that could be integrated into next-generation ACT manufacturing and optimization. The study provides technical details that may help other groups evaluate how surface properties affect trafficking and tumor engagement in vivo.